Anti-Human GM-CSF (Granulocyte-macrophage colony stimulating growth factor) Recombinant Antibody (F1) (CAT#: TAB-180CT)

Figure 1 Neutralization by mAbs against GM-CSF of bioactivity of GM-CSF.

Washed TF-1 cells were incubated with titrations of the indicated mAbs and 200 pg/mL rhGM-CSF. After 4 d, metabolic activity of TF-1 cells was measured by the water-soluble tetrazolium assay.

Wang, Y., Thomson, C. A., Allan, L. L., Jackson, L. M., Olson, M., Hercus, T. R., ... & Waddell, T. K. (2013). Characterization of pathogenic human monoclonal autoantibodies against GM-CSF. Proceedings of the National Academy of Sciences, 110(19), 7832-7837.

Figure 2 Neutralization by mAbs against GM-CSF of bioactivity of GM-CSF.

mAb F1 inhibits CD11b expression level on primary neutrophils stimulated by GM-CSF. Titrations of F1 mAb were added to heparinized blood with a high concentration of GM-CSF (10 ng/mL).

Wang, Y., Thomson, C. A., Allan, L. L., Jackson, L. M., Olson, M., Hercus, T. R., ... & Waddell, T. K. (2013). Characterization of pathogenic human monoclonal autoantibodies against GM-CSF. Proceedings of the National Academy of Sciences, 110(19), 7832-7837.

Figure 3 Neutralization of the bioactivity of GM-CSF by mAbs against GM-CSF.

After incubation with GM-CSF and titrations of mAb F1, PE-labeled anti-CD11b antibodies were added to the blood and held on ice. The cells were washed, and the neutrophils were gated on high side-scatter. Shown are histograms of fluorescence with different concentrations of mAb F1. Positive controls were GM-CSF (10 ng/mL) with no F1, and negative controls were neutrophils with no GM-CSF and F1 (300 ng/mL).

Wang, Y., Thomson, C. A., Allan, L. L., Jackson, L. M., Olson, M., Hercus, T. R., ... & Waddell, T. K. (2013). Characterization of pathogenic human monoclonal autoantibodies against GM-CSF. Proceedings of the National Academy of Sciences, 110(19), 7832-7837.

Figure 1 Anti-Human GM-CSF Recombinant Antibody (F1) (TAB-180CT) in SDS-PAGE

SDS-PAGE analysis of TAB-180CT in non-reduced (lane 1) and reduced (lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.

Figure 2 Anti-Human GM-CSF Recombinant Antibody (F1) (TAB-180CT) in SEC-HPLC

The purity of this antibody is> 95% as determined by SEC-HPLC.

Figure 3 Anti-Human GM-CSF Recombinant Antibody (F1) in WB.

Western blot analysis of TAB-180CT was performed by loading Human GM-CSF Protein in reduced condition Lane 1, Lane 2, Lane 3 (0.1 μg, 0.3 μg, 0.6 μg) onto a 15% Tris-HCl polyacrylamide gel. Proteins were transferred to an NC membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-180CT (2 μg/mL) and HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Figure 4 Anti-Human GM-CSF Recombinant Antibody (F1) in DB.

Dot Blot analysis of TAB-180CT was performed by coating with Human GM-CSF Protein.
TAB-180CT incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000).

Figure 5 Anti-Human GM-CSF Recombinant Antibody (F1) in ELISA.

ELISA analysis of TAB-180CT was performed by coating with Human GM-CSF Protein. Then blocked with BSA and incubated with TAB-180CT. The HRP-conjugated goat anti human IgG as a secondary antibody (1: 2000). Detection was performed using TMB
substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.